As of 2024-12-11, the Intrinsic Value of Dechra Pharmaceuticals PLC (DPH.L) is
460.17 GBP. This DPH.L valuation is based on the model Discounted Cash Flows (Growth Exit 10Y).
With the current market price of 3,866.00 GBP, the upside of Dechra Pharmaceuticals PLC is
-88.10%.
The range of the Intrinsic Value is 126.91 - 1,818.35 GBP
460.17 GBP
Intrinsic Value
DPH.L Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(309.36) - (80.55) |
(264.28) |
-106.8% |
| DCF (Growth 10y) |
126.91 - 1,818.35 |
460.17 |
-88.1% |
| DCF (EBITDA 5y) |
199.73 - 517.23 |
353.44 |
-90.9% |
| DCF (EBITDA 10y) |
468.84 - 1,048.25 |
735.18 |
-81.0% |
| Fair Value |
-122.53 - -122.53 |
-122.53 |
-103.17% |
| P/E |
(457.78) - (505.33) |
(490.13) |
-112.7% |
| EV/EBITDA |
364.29 - 1,628.06 |
884.11 |
-77.1% |
| EPV |
634.44 - 1,055.32 |
844.88 |
-78.1% |
| DDM - Stable |
(250.07) - (1,141.56) |
(695.82) |
-118.0% |
| DDM - Multi |
236.35 - 868.72 |
375.33 |
-90.3% |
DPH.L Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
4,401.32 |
| Beta |
1.15 |
| Outstanding shares (mil) |
1.14 |
| Enterprise Value (mil) |
4,831.43 |
| Market risk premium |
5.98% |
| Cost of Equity |
8.40% |
| Cost of Debt |
4.60% |
| WACC |
7.89% |